Abiopharma

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

Roots Reports First Quarter Fiscal 2026 Results & Business Update

Ferguson Enterprises Inc. (“Company”): Execution of Rule 10b5-1 Plan

Ferguson Enterprises Inc. (“Company”): Execution of Rule 10b5-1 Plan

Invitation Homes Announces Cash Dividend

Build-A-Bear Workshop Completes Planned CEO Succession

Booz Allen Hamilton to Host Conference Call to Discuss First Quarter Fiscal 2027 Results on Friday, July 24, 2026

BeOne在EHA 2026上展示具有里程碑意義的80歲以上CLL病患第三期資料，進一步證實BRUKINSA的獲益

BeOne、EHA 2026で80歳以上のCLL患者を対象とした画期的な第3相データを発表、BRUKINSAのベネフィットを裏付け

BeOne présente des données historiques de phase 3 chez des patients atteints de LLC âgés de 80 ans et plus lors du congrès EHA 2026, confirmant ainsi les bénéfices de BRUKINSA